The Medicines Act (1981) and its amendments regulate the manufacture, sale and supply of medicines, medical devices and related products in New Zealand. Medications are approved for supply under the provisions of this Act. Supply and administration of unapproved medications is permitted. When this occurs, the supplier must report this to the Director-General of Health. Additionally, the patient must be informed of the unapproved status of the drug and be advised of the forwarding of information related to their health care to a third party. For apparently commercial reasons, approval has not been sought for a number of formulations of medications commonly used in anaesthesia practice.
The Medicines Act (1981) with its amendments regulates the manufacture, sale and supply of medicines, medical devices and related products in New Zealand. Medications are approved for supply under the provisions of this Act. Approval is sought by the manufacturers or distributors from the Ministry of Health. It must be established that there is a body of evidence supporting the safety and efficacy of the medication for approval to be granted.
The Act is permissive, such that "An authorised prescriber maysell or supply, or procure the sale or supply of, any medicine… [and] administer, or procure the administration of, any medicine to [a] patient" 1 . This includes both medicines approved for supply and unapproved medicines.
Approval is granted to specific commercial formulations of a medicine, rather than to a --medicine in general. A number of medications used in anaesthesia are supplied as formulations unapproved by the regulator. Some have never been approved (e.g. etomidate). Others have previously been approved, but a new supplier has not sought approval for their formulation (e.g. thiopentone). All of these drugs have a small market share relative to the cost of the approval process (a minimum of NZ$120,000 [Personal communication, Michelle Gibbs, Researched Medicines Industry Association of New Zealand]).
The Act anticipates that some medicines that are internationally in common use may not be approved for use in New Zealand. The supply and administration of these unapproved medications is provided for by Section 29 of the Act. This states that the lack of approved status shall not prevent "the supply… of any medicine required… for the treatment of a… patient… or the administration by any medical practitioner of any such medicine to any such patient" 2 . However, when unapproved medications are supplied, it is required that the supplier report this to the Director-General of Health 3 . The rationale is to allow follow-up of an individual patient if a problem is detected 4 .
The information required includes the names of the medical practitioner and patient, the name of the medication and the time and place of supply.
The prescription and administration of medicines must comply with the Code of Health and Disability Services Consumers' Rights. Of particular relevance are the rights to be fully informed and to give informed consent 5 . The implication is that, even in the situation that an unapproved medication is administered for a well recognised indication, supported by evidence, the patient must be informed of the unapproved status of the drug if the practitioner is to comply with these rights. In addition to this, the Health Information Privacy Code requires that the patient be advised of the forwarding of this information to a third party 6 .
There has been no published literature on the impact of this legislation on the practice of anaesthesia in New Zealand. This aim of this survey was to investigate how commonly anaesthetists administer drugs that are unapproved by the Medicines Act, how often the requirements for informed consent are met and what perceived impact, if any, the status of these medications has on patient care.
MATeRIAlS AND MeTHODS
every consultant anaesthetist registered with the Australian and New Zealand College of Anaesthetists (ANZCA) and resident in New Zealand was anonymously surveyed. The survey was designed according to accepted principles of good survey design 7 . It was pre-tested on a small cohort of anaesthetists prior to use. A covering letter explaining the intention of the survey and briefly summarising some aspects of the Medicines Act and Section 29 of the Act was included. A reminder letter was sent to those who had not replied to the initial survey after approximately two months.
A tertiary hospital pharmacy stocked 86 unapproved medications at the time of the survey (Personal communication, Margaret Cole, Senior Operational Pharmacist, Counties Manukau District Health Board, Auckland, New Zealand). Products used specifically by anaesthetists were co-phenylcaine nasal spray, etomidate, halothane, metaraminol, methohexitone and thiopentone.
Data analysis
Descriptive statistical analysis was performed using Microsoft excel (Microsoft Corp., Redmond, WA, u.S.A.). All data were categorical and thus are described in percentages or proportions.
These were rounded to the nearest whole number. Statistical significance was assessed with Chi square testing using a web-based calculator 8 . Statistical significance was considered to occur at P <0.05.
ReSulTS
A total of 399 surveys were distributed. The initial response rate was 66% (265 replies). Following the second distribution the cummulative response rate was 77% (309 replies). eleven respondents did not complete the survey. Reasons given included retirement from practice (6), absence from the country (2), not currently practising anaesthesia (2) and other (1) . Two responses to the survey were excluded from analysis due to uncertainty as to whether they were duplicated responses. Overall, 296 responses were eligible for analysis. This represents 74% of all New Zealand ANZCA Fellows currently resident in New Zealand.
The denominator varies in each question as not all respondents replied to every question.
Area of practice
Over half of the respondents (56%) described their practice as predominantly in the public sector, 12% described their practice as predominantly private and 31% stated their practice was both. Of the 91 (31%) who described their practice as predominantly in subspecialty anaesthesia, 15 detailed two subspecialty areas and one identified three.
Drugs used in the month preceding response to the survey
There were 295 replies to this question. All the drugs listed in the methods above had been administered. Over three-quarters of respondents had administered at least one of the drugs in the month preceding the survey and the majority of respondents (58%) had administered more than one. The drug administered by most anaesthetists was metaraminol (47%) followed by etomidate (37%) (Figure 1 ).
Frequency of administration
There were 291 replies. The listed drugs were reported to have been administered "weekly or more often" by 39% of respondents. Twenty-six percent reported administration "every few weeks". Seventeen percent indicated they administer these drugs "every few months" and the same proportion administered them "rarely or never".
Data collection
eighty percent of anaesthetists worked in institutions which had a method of collecting the details of patients to whom Section 29 drugs were administered. eleven percent stated that their hospital had no such system and 9% did not know. It was significantly more likely (P <0.001) that there was a system of collecting patient details if the anaesthetists described their practice as predominantly public than predominantly private or a mix.
Informed consent
Five anaesthetists (2%) responded that they always inform patients about the possible use of Section 29 drugs in their anaesthetic; 78% never informed patients and 20% sometimes did.
Departmental policy
Sixty percent of anaesthetists did not know whether the departments in which they worked had a policy exempting them from the requirements to gain specific consent for drugs that have an established body of evidence but which are unapproved: 24% worked in institutions with such a policy, 16% did not.
Impact on practice
eighty-three percent of anaesthetists did not feel the unapproved status of the drugs affected their practice.
Patient care
Sixty-four percent of respondents believed patient care had been compromised by the reduced availability of Section 29 drugs, while 36% felt this was not the case. Those who reported administering a Section 29 drug "every few weeks" or more often were significantly more likely to believe patient care had been compromised than less frequent prescribers (70% vs. 54%, P <0.025). There was no statistically significant difference in opinions about compromise to patient care between anaesthetists who identified a subspecialty area of practice and those who did not.
DISCuSSION
The results of this survey provide new information about the use of unapproved medicines in anaesthesia practice in New Zealand.
A satisfactory response rate was obtained. using information held by ANZCA limits this survey to College members. Specialists registered only with overseas colleges were not surveyed. Based on relevant work force data 9 it is likely that approximately 20 anaesthetists were not contacted by this survey. Given this small number and the high response rate, this survey generates data which is generalisable. Nevertheless, this survey has the potential for bias inherent in self-reported, retrospective data.
Three-quarters of respondents had administered at least one of the surveyed medications in the month preceding the survey. Two-thirds of respondents administer Section 29 medications every few weeks or more often. In addition to allowing the supply and administration of unapproved medicines, the Medicines Act allows the unreported use of approved medicines for unapproved purposes. This is common in anaesthesia, as it is in many branches of medicine 10 . Such 'off label' use was outside of the scope of this study, but may expand the number of anaesthetists who administer a drug under this legislation.
The majority of respondents worked in an institution which has a system for collecting data required by the Act. Twenty percent of respondents worked in departments where such a system does not exist, or were unsure if it existed (so presumably this information is not collected for their patients).
The rationale for collecting this information is to allow follow-up of patients. This is relevant to many unapproved medications which may be new, experimental or administered chronically in the treatment of rare conditions. It is clearly desirable to be able to follow up patients in these circumstances. Contrast this with a previously approved medication administered in the closely monitored environment of an anaesthetic. It is not clear how this requirement of the law provides any protection to patients, much less that any protection is required. except in an emergency, every medical practitioner must obtain informed consent prior to administering a drug or performing a procedure.
With respect to unapproved medicines, the patient must be informed of the status of the drug and the degree of support for the drug for the indication. This survey establishes that it is rare for informed consent to be sought, with 78% of respondents never informing their patients about the possible use of Section 29 drugs in their care. This indicates that a large proportion of New Zealand anaesthetists are knowingly acting 'outside the law' in this area.
The terms "unlicensed", "unapproved" and "unregistered" are all used to refer to medicines that are supplied under Section 29 of the Medicines Act. The term "unapproved" has been used throughout as it is the term used by the Ministry of Health. It is a problematic term implying that these medications do not meet a reasonable standard of safety or utility. This is not the case with the anaesthetic drugs concerned. All of the medications in this survey have an established body of evidence that support their safety and utility, and they remain 'unapproved' mainly for commercial reasons. To expect a higher standard of consent for administration of these medications than for newer drugs that are approved but may have a lesser body of evidence, may contribute to the low rate of compliance with this requirement of the legislation.
The administration of medicines in anaesthesia is unique. There are few areas of medicine where it is routine for a medical practitioner to prepare and administer a great number of medications to a patient in such a dynamic situation as an anaesthetic. To discuss the use, or potential use, of an individual unapproved drug in an anaesthetic that is the result of complex pharmacologic and physiologic interactions is unlikely to convey to patients information that will affect their decision-making. Informed consent requires that a competent patient freely gives consent to treatment after being given "information that a reasonable consumer, in that consumer's circumstances, would expect to receive" 5 . It is unlikely that the unapproved status of well established medications constitutes "information that may dissuade the consumer from agreeing to the use of the medicine" 4 . It is unclear if an adverse outcome related to an unapproved medication for which a patient had not given informed consent may expose anaesthetists to legal liability.
Of concern, two-thirds of respondents stated that the reduced availability of these drugs has compromised patient care. This question in the survey was based on the common perception that Section 29 of the Medicines Act limits the availability of unapproved medications. Contrary to the views of a number of those surveyed, all the listed drugs are able to be obtained in New Zealand and all are used. However, continuity of supply is not guaranteed. This is illustrated by the recent situation where manufacturing problems resulted in a disruption to the supply of the approved formulation of adrenaline 11 .
A trans-Tasman regulatory body (Australia New Zealand Therapeutic Products Authority) has been proposed-the establishment of which would result in the repeal of the Medicines Act 12 . At the time of writing, the proposed Therapeutics Products and Medicines Bill has not gathered support in the New Zealand Parliament, but remains on the Parliamentary Order Paper for future review. Such a single regulatory agency would have reduced compliance costs resulting in increased availability of the medications discussed here.
It is argued above that non-compliance with the requirements of this legislation does not place patients at risk, or compromise informed consent as a whole. Regardless of this justification, the majority of New Zealand anaesthetists are practising in defiance of the law.
In conclusion, this study has established that in New Zealand, anaesthetists are frequently administering a number of drugs that are 'unapproved' and thus subject to the requirements detailed in Section 29 of the Medicines Act 1981. It is argued that the frequent non-compliance with the legislation reported in this study does not place patients at undue risk or compromise informed consent for anaesthesia as a whole.
